# A Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis

> **NCT03443024** · PHASE2 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 280 (actual)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **BIOLOGICAL:** Lebrikizumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03443024
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-01-30
- **Primary completion:** 2019-02-07
- **Final completion:** 2019-05-23
- **Target enrollment:** 280 (ACTUAL)
- **Last updated:** 2021-05-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03443024

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03443024, "A Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03443024. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*